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Combined treatment for Duchenne muscular dystrophy 




In preclinical models for Duchenne muscular dystrophy, dystrophin restoration during AAV-
U7-mediated exon-skipping therapy decreases drastically after one year in treated muscles. 
This decline in benefit is strongly correlated with loss of the therapeutic AAV genomes, 
probably due to alterations of the dystrophic myofiber membranes. To improve the 
membrane integrity of the dystrophic myofibers at the time of AAV-U7 injection, mdx muscles 
were pre-treated with a single dose of peptide-phosphorodiamidate morpholino (PPMO) 
antisense oligonucleotides that induced temporary dystrophin expression at the sarcolemma. 
The PPMO pre-treatment allowed efficient maintenance of AAV genomes in mdx muscles 
and enhanced the long-term effect of AAV-U7 therapy with a ten-fold increase of the protein 
level after six months. It is also beneficial to AAV-mediated gene therapy with transfer of 
micro-dystrophin cDNAs into muscles. This combined approach will allow the use of lower 






The dystrophinopathies are pathologies caused by anomalies in the DMD gene that encodes 
the sub-sarcolemmal protein dystrophin. This protein is absent or drastically diminished in 
Duchenne muscular dystrophy (DMD) while it is present but qualitatively and/or quantitatively 
altered in the Becker muscular dystrophy (BMD). The dystrophin structure (central rod-
domain made of 24 spectrin-like repeats) tolerates large internal deletions (Harper et al., 
2002) which led to the development of two main therapeutic strategies: gene therapy with 
transfer of micro-dystrophin cDNAs in muscles, and targeted exon skipping. Both 
approaches have shown encouraging results using adeno-associated viral (AAV) vectors, 
which allow efficient gene transfer into muscles. AAV-mediated delivery of micro-dystrophins 
into dystrophin-deficient mice has shown remarkable efficiency (Gregorevic et al., 2006; Koo 
et al., 2011; Shin et al., 2013) leading to the initiation of an early-phase clinical trial (Mendell 
et al., 2010).  
Exon skipping converts an out-of-frame mutation into an in-frame mutation leading to an 
internally deleted but partially functional dystrophin. This therapeutic approach has 
demonstrated some success using antisense oligonucleotides (AONs), but recent studies 
showed limited clinical benefit (Cirak et al., 2011; Goemans et al., 2011; Mendell et al., 2013; 
Voit et al., 2014). The novel generation of AON chemistries, in particular tricyclo-DNA 
(tcDNA) (Goyenvalle et al., 2015) and peptide-phosphorodiamidate morpholino 
oligonucleotide (PPMO) (Betts et al., 2012; Betts et al., 2015), display unprecedented 
degrees of dystrophin restoration in skeletal muscles, but also restore dystrophin expression 
in the heart and, to a lesser extent, in the brain for the tcDNAs. AONs have the enormous 
advantage of not being immunogenic but require regular administration to maintain 
therapeutic benefit.  
The antisense sequences can be expressed in skeletal or cardiac muscles via a small 
nuclear RNA such as U7snRNA or U1snRNA (Brun et al., 2003; Denti et al., 2006; 
Goyenvalle et al., 2004). These therapeutic molecules are vectorised in AAV particles which 
ensure a permanent production of the antisense in dystrophin-deficient murine models (Denti 
4 
 
et al., 2006;Goyenvalle et al., 2012;Goyenvalle et al., 2004), as well as in the dystrophin-
deficient dog GRMD (Bish et al., 2012; Le Guiner et al., 2014; Vulin et al., 2012). In all 
dystrophic models, a one-shot treatment of AAV-U7snRNA (AAV-U7) was sufficient to attain 
substantial levels of restored dystrophin, which is associated with a significant improvement 
of the muscle force (Denti et al., 2006; Goyenvalle et al., 2012; Goyenvalle et al., 2004; Le 
Guiner et al., 2014; Vulin et al., 2012).  
Despite the high efficiency of AAV-U7 strategy, we recently showed that dystrophin levels 
decreased significantly after one year in various skeletal muscles in the severely dystrophic 
dystrophin/utrophin knockout (dKO) mouse and in the GRMD dog (Le Hir et al., 2013; Vulin 
et al., 2012). This decline in dystrophin was strongly correlated with viral genome loss, most 
likely due to alterations of the dystrophic myofiber membranes. In the context of an AAV-U7 
clinical trial for DMD, AAV genome fate in dystrophic muscles is of major importance since 
the viral capsid immunogenicity currently limits repeated treatment (Lorain et al., 2008). We 
recently investigated the viral genome fate in muscles of the moderately dystrophic mdx 
mouse and showed that non-therapeutic viral genomes were lost quickly after the injection 
and that this loss was diminished when high doses of viral genomes restored dystrophin at 
the sarcolemma (Le Hir et al., 2013).  
The goal of the present study was to avoid viral genome loss by pre-conditioning the 
dystrophic muscles for AAV injections. We showed for the first time that an AAV-U7 
threshold dose was required to restore efficiently the dystrophin expression in the mdx 
mouse. We also demonstrated that therapeutic AAV genomes were lost from mdx muscle 
during the time interval between the AAV-U7 injection and the occurrence of dystrophin in 
sufficient quantity at the sarcolemma. Moreover, induction of transient high dystrophin 
expression at the sarcolemma of myofibers with peptide-phosphorodiamidate morpholino 
(PPMO) AONs allowed efficient preservation of AAV genomes in mdx muscles. Importantly, 
the efficacy of AAV-U7-mediated exon skipping as well as AAV-mediated micro-dystrophin 
gene therapy was markedly improved. Therefore, avoiding viral genome loss after AAV 
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injection by AON pre-treatment could help achieve a threshold dose of AAV genomes 
needed for efficient long-term restoration of dystrophin in mdx muscles.  
Considering that more than 80% of DMD mutations are eligible for the personalized medicine 
involving the skipping of a single or of multiple exons (Aartsma-Rus et al., 2009), this 
combined therapy approach could in theory benefit up to 80% of DMD patients.  
 
Results 
Dystrophin rescue kinetics highlight a threshold dose of AAV-U7  
We first investigated the kinetics of dystrophin rescue at different doses of therapeutic AAV1 
vector in muscles of mdx mice that carry a nonsense mutation in exon 23 of the Dmd gene 
(Sicinski et al., 1989). We used an AAV1 vector encoding an U7snRNA (AAV1-U7ex23) 
allowing efficient exon 23 skipping and therefore dystrophin rescue in mdx muscles 
(Goyenvalle et al., 2004). High (1E+11 viral genome or vg), intermediate (3E+10 vg) and low 
(1E+10 vg) doses of this vector were injected into mdx Tibialis anterior (TA) muscles and 
dystrophin protein levels were quantified in these muscles by western blotting 3, 6 and 12 
weeks post-injection (Fig. 1a&b). The high dose of AAV1-U7ex23 allowed strong dystrophin 
expression (around 35% of normal dystrophin level) at 3 weeks after the injection, and 
reached a plateau (50-70%) by six weeks. At the intermediate dose, the kinetics of 
dystrophin restoration was delayed with only 3% of dystrophin expression at 3 weeks, 40% at 
6 weeks and 70% at 12 weeks. At the low dose, dystrophin rescue was around 2% at 3 
weeks and remained low even by 12 weeks post-injection. These data showed that the low 
dose of AAV1-U7ex23 was below a threshold level required for an effective restoration of 
dystrophin. 
 
The time interval between the AAV injection and the dystrophin rescue is decisive for 
viral genome maintenance 
In the kinetic experiments of dystrophin rescue, the number of viral genomes in TA muscles 
quantified by quantitative PCR (qPCR) was stable for each AAV1-U7ex23 dose between 3 
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and 12 weeks post-injection (Fig. 1c). The 3-fold increment applied between the three 
injected doses correlated to AAV genome levels with 2.5-fold more vg in the intermediate 
dose injected mdx muscles than in the low injected ones. A 5-fold higher factor was 
quantified between the high and intermediate dose injected muscles indicating that with 
higher dose more viral particles are retained in the target tissue. These results are consistent 
with our published observation that AAV1-U7ex23 genomes are maintained at high dose 3 
weeks post-injection in mdx muscles compared to wild-type (wt) muscles, while they are 
poorly preserved at low and intermediate doses (Le Hir et al., 2013). Therefore, the viral 
genome loss observed at low and intermediate doses in the mdx muscles occurred 
principally before three weeks, when dystrophin is not yet present at the sarcolemma, and 
not during the following weeks. In this sense, at the intermediate dose the delay observed in 
dystrophin rescue compared to high dose (Fig. 1a&b) might be responsible for the viral 
genome loss observed at this dose but not at high dose. Hence, the time interval between 
the AAV injection and the presence of a functional dystrophin in sufficient quantity at the 
sarcolemma is decisive for viral genome maintenance. 
 
Viral genomes are efficiently maintained in Pip6a-PMO rescued mdx muscles  
To avoid AAV genome loss following the AAV injection, dystrophin expression was induced 
temporarily at the sarcolemma of mdx TA myofibers by a single injection of Pip6a-PMO AON, 
a PPMO that is particularly efficient for mdx exon skipping (Betts et al., 2012). A non-
therapeutic vector carrying non-specific sequence (AAV-U7scr, 1E+11 vg) was injected in 
the same muscles two weeks after the PPMO injections (Fig. 2a) when dystrophin rescue 
was already optimal (Supplementary data 1). We previously showed that this high dose of 
non-therapeutic genomes was drastically lost after three weeks since the sequence is unable 
to rescue dystrophin expression (Le Hir et al., 2013). Following PPMO pre-treatment and 
three weeks after AAV1-U7scr injection, immunofluorescence analysis revealed a strong 
dystrophin restoration with appropriate sarcolemmal location in mdx injected muscles (Fig. 
2b), between 56 to 98% of normal dystrophin levels when quantified by western blotting 
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(Fig. 2c), illustrating the high PPMO efficiency for dystrophin restoration. The viral genome 
content was 6 times lower in non PPMO-treated mdx muscles than in wt muscles, as already 
shown (Le Hir et al., 2013). In contrast, the PPMO-treated mdx group had significantly 
increased numbers of viral genomes, with levels exceeding that of wt muscles, although not 
to significance (Fig. 2d). Therefore, a significant dystrophin expression induced by PPMO 
pre-treatment at the time of AAV1-U7scr injection protects against the rapid loss of AAV1-
U7scr genomes in mdx muscles comparable to what is observed in wt muscles. 
 
Pip6a-PMO pre-treatment allows important dystrophin rescue at low AAV-U7ex23 dose 
after 6 months  
We then evaluated the long-term benefit of an AON pre-treatment on the dystrophin rescue 
via AAV1-U7ex23. Pip6a-PMO AONs were injected into mdx TAs two weeks before injection 
of low dose of AAV1-U7ex23 vector (1E+10 vg) (Fig. 3a), which without pre-treatment 
allowed only a weak dystrophin rescue (2%, Fig. 1a&b). Six months later, levels of exon 23 
skipping analysed by nested RT-PCR (Fig. 3b) and quantified by qPCR (Fig. 3c) in mdx TAs 
treated with AAV1-U7ex23 or PPMO alone were low as expected, respectively 9 and 6% of 
skipped transcripts, leading to the synthesis of rescued dystrophin around 2% of the normal 
level (Fig. 3e). Conversely, TAs treated sequentially with PPMOs then with AAV1-U7ex23 
showed 54% of skipped transcripts (Fig. 3c) and a dystrophin at 20% of the normal level of 
dystrophin (Fig. 3e). Moreover, the viral genome number was 8-fold higher in the combined 
PPMO/AAV1-U7ex23 treated muscles than in AAV1-U7ex23 only injected muscles (Fig. 3d). 
These data demonstrate that the PPMO pre-treatment induced maintenance of the 
therapeutic U7ex23 genomes in mdx muscles six months after the AAV-U7 injections and 
remarkably resulted in a 10-fold increase of the rescued dystrophin amount.  
 
Pip6a-PMO pre-treatment significantly increases the efficacy of AAV1 mediated micro-
dystrophin gene therapy  
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To evaluate the efficacy of an AON pre-treatment on AAV-micro-dystrophin gene therapy, we 
injected Pip6a-PMO AONs into mdx TAs two weeks before injection of AAV1-MD1 vector 
(1E+10 vg) expressing a murine micro-dystrophin under the control of the muscle-restrictive 
Spc5-12 promoter (Foster et al., 2008) (Fig.4a). Four weeks later, a strong dystrophin 
restoration was observed in PPMO-treated mdx TAs induced by the PPMO pre-treatment 
(Fig. 4c). AAV genome copy number and micro-dystrophin expression were 3-fold higher in 
the PPMO/AAV1-MD1 treated muscles than in AAV1-MD1 only treated muscles (Fig. 4b&c), 
illustrating the PPMO pre-treatment benefit on AAV-micro-dystrophin gene therapy. This 
experiment demonstrates that the AON pre-treatment is capable of enhancing all AAV-based 
gene therapies for DMD. 
 
Discussion 
We previously showed that therapeutic AAV genomes are rapidly lost from dystrophic 
muscles during AAV-U7-mediated exon-skipping therapy (Le Hir et al., 2013). However, a 
strong dystrophin rescue induced by high dose (1E+11 vg) of AAV-U7 in mdx muscles 
prevents this viral genome loss. We show here that, at this high dose, the dystrophin 
restoration was not only maximal but also rapid after the therapeutic injection. With a 3-fold 
lower viral genome dose (intermediate dose) injected in the dystrophic muscles, the 
dystrophin synthesis was delayed but became maximal with albeit a massive genome loss 
occuring during the first weeks post-injection. These data demonstrated that a delay in 
dystrophin synthesis is sufficient to cause a substantial viral genome loss that could 
significantly limit the long-term therapeutic benefit of AAV therapies for DMD. Therefore, the 
initial period between the therapeutic injection and the presence of a functional dystrophin at 
the myofiber sarcolemma is decisive for viral genome maintenance in dystrophic muscles; 
the sooner dystrophin is present at the sarcolemna, the more AAV genomes are maintained 
in mdx muscles. 
We demonstrate also that a low dose of AAV-U7ex23 was not sufficient to induce significant 
dystrophin restoration while the intermediate dose that contained only 3-fold more viral 
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genomes induced a high level of dystrophin restoration as just described. This observation 
suggests that the low dose of therapeutic vector is below a threshold necessary to restore 
significant dystrophin expression and thus to allow long-term maintenance of viral genomes. 
The existence of this threshold level is crucial for AAV-U7 therapy meaning that our goal is to 
reach and maintain this threshold dose of therapeutic viral genomes inside the dystrophic 
myofibers in order to obtain a sustainable therapeutic benefit. 
 
To slow down the loss of therapeutic viral genomes from dystrophic muscles and achieve 
long-term restoration of dystrophin expression, we previously proposed recurrent systemic 
injections of AONs to prevent the progressive reappearance of a dystrophic phenotype 
caused by the partial loss of AAV genomes over time (Le Hir et al., 2013). Instead of these 
successive therapies, we demonstrate here the synergistic benefit of the reciprocal treatment 
combination with first a single AON injection to restore dystrophin at the myofiber 
sarcolemma and secure membrane integrity followed by a single systemic injection of AAV-
U7 vector to induce a strong and long-lasting expression of dystrophin in muscles. A 
significant dystrophin rescue by PPMO pre-treatment at the time of AAV-U7 injections allows 
an efficient maintenance of the viral genomes in mdx muscles three weeks later. Additionally, 
this initial maintenance of viral genomes increases dystrophin restoration by AAV-U7, around 
8-fold at RNA level and 10-fold at protein level up to six months later. Of course, this does 
not rule out our previous hypothesis that AON administration subsequent to AAV treatment 
could supplement AAV-mediated dystrophin restoration and act so as to maintain or even 
increase dystrophin levels, especially as life-long treatment will be required in DMD patients.  
We showed also that an AON pre-treatment confers an increased benefit to AAV-mediated 
micro-dystrophin cDNA transfer into mdx muscles. Indeed, four weeks later, micro-dystrophin 
expression was already 3-fold higher in PPMO-treated mdx mouse compared to untreated 
one.  
The PPMO pre-treatment results in substantial dystrophin expression at the time of AAV-U7 
injection that likely reduces the membrane abnormalities leading to AAV genome loss before 
10 
 
AAV-U7 induced dystrophin expression occurs. Once established, an AAV-U7 mediated high 
dystrophin expression will be maintained because it will by itself prevent transgene loss (Le 
Hir et al., 2013). The same scenario is conceivable for micro-dystrophin gene therapy. By 
allowing the maintenance of high viral genome content in the decisive period between AAV 
injection and AAV-mediated transgene expression in the treated dystrophic muscles, PPMO-
mediated dystrophin restoration guarantees a higher therapeutic benefit of the AAV based 
therapy compared to direct AAV injection. Additionally, in condition of poor AAV transduction, 
especially with systemic delivery some muscles are less transduced than others (Louboutin 
et al., 2005), PPMO pre-treatment could help reaching in these muscles the threshold dose 
of AAV genomes needed to restore efficiently dystrophin in mdx muscles. 
The fact that the rescue effect on AAV genomes was relatively lower for AAV-MD1 as 
compared to AAV-U7 mediated treatment can likely be explained by the direct transcription 
and overexpression of the micro-dystrophin cDNA resulting in more rapid dystrophin-
mediated membrane sealing. In contrast, the U7-mediated exon skipping is dependent on 
the U7-antisense transcription and its action on intrinsically produced dystrophin mRNA 
which delays membrane sealing and thereby favours increased AAV genome loss. 
 
The viral genome loss is certainly due to the fragility of the dystrophic muscle fibers that 
undergo cycles of necrosis/generation as we observed a similar loss of vector genomes in 
cardiotoxin-treated normal muscles (Le Hir et al., 2013). However, other causes could 
participate to the process of viral genome loss from the dystrophic muscles. Dystrophic 
myofibers present abnormally leaky membranes that could passively loose the viral 
genomes, as exemplified by the creatine kinase (CK) activity greatly elevated in sera of 
Duchenne patients and preclinical animal models or conversely by Evans blue uptake into 
dystrophic muscle (Straub et al., 1997). In addition, AAV vectors were also found associated 
with exosomes termed vexosomes in culture media of AAV producer cells (Maguire et al., 
2012). Interestingly, lack of dystrophin at the sarcolemma of mdx myofibers was shown to 
lead to an increased excretion of exosomes that was partially restored by dystrophin rescue 
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(Duguez et al., 2013), suggesting that therapeutic viral vectors might also be lost through 
excretion via exosomes from the dystrophic myofibers. However, such secretion 
mechanisms of AAV vectors remain to be further investigated in vivo. Therefore, AON-
mediated dystrophin restoration could reduce these membrane abnormalities and thus 
further preserve the therapeutic viral genomes in the dystrophic myofibers.  
Recently, transcripts derived from AAV vectors have been shown to be destabilized by 
oxidative damage caused by free radicals, reducing the transgene expression in dystrophic 
muscles (Dupont et al., 2015). Interestingly, high expression of micro-dystrophin was able to 
significantly reduce the proportion of oxidized transcripts in GRMD dog muscles showing a 
direct correlation between the oxidative stress of the myofibers and the dystrophic 
phenotype. Hence, lowering the oxidative status by AON pre-treatment might also facilitate a 
high AAV transgene expression and help reaching the threshold of therapeutic viral genome 
number necessary to allow a long-lasting benefit of AAV therapies. 
On the eve of clinical trials using AAV-based therapies for DMD patients, this study 
underscores the strong impact of combined approaches to improve the benefit of AAV-based 
therapies allowing the use of lower and thus safer vector doses for a larger level of 
dystrophin expression in the long term.  
 
Materials and Methods 
Viral vector production and animal experiments 
A three-plasmid transfection protocol was used with pAAV(U7smOPT-SD23/BP22) 
(Goyenvalle et al., 2004), pAAV(U7smOPT-scr) (Le Hir et al., 2013) and codon optimized 
pΔR4-R23/ΔCT (MD1) (Foster et al., 2008) plasmids for generation of single-strand AAV1-
U7ex23, AAV1-U7scr and AAV1-MD1 vectors. Three-month-old mdx mice were injected into 
the Tibialis anterior (TA) muscles with 1 nmole of Pip6a-PMO oligonucleotides 
(GGCCAAACCTCGGCTTACCTGAAAT) (Betts et al., 2012). Additionally, 50µl of AAV1-
U7scr, AAV1-U7ex23 or AAV1-MD1 containing 1E+10, 3E+10 or 1E+11 viral genomes (vg) 
were injected into C57BL/6 (wt) or mdx TAs. These animal experiments were performed at 
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the Myology Research Center, Paris, France, according to the guidelines and protocols 
approved by the Institutional Review Board. A minimum of four mice were injected per group 
for each experiment. At sacrifice, muscles were collected, snap-frozen in liquid nitrogen-
cooled isopentane and stored at -80°C. 
 
Viral genome quantification 
Genomic DNA was extracted from mouse muscles using Puregene Blood kit (Qiagen). Copy 
number of AAV genomes and genomic DNA were measured on 100ng of genomic DNA by 
absolute quantitative real-time PCR on a StepOnePlusTM (Applied Biosystems) using the 
TaqmanR Universal Master Mix (Applied Biosystems). Primers (forward: 
CTCCATCACTAGGGGTTCCTTG and reverse: GTAGATAAGTAGCATGGC) and probe 
(TAGTTAATGATTAACCC) were used to specifically amplify the viral genome sequence. As 
a reference sample, a pAAV plasmid was 10-fold serially diluted (from 107 to 101 copies). All 
genomic DNA samples were analysed in duplicates. 
 
RT-PCR analysis  
Total RNA was isolated from mouse muscle with NucleoSpin® RNA II (Macherey-Nagel), 
and reverse transcription (RT) performed on 200ng of RNA by using the Superscript™ II and 
random primers (Life technologies). Non-skipped and skipped dystrophin transcripts were 
detected by nested PCR and quantified as described (Goyenvalle et al., 2012).  
 
Western blot analysis 
Protein extracts were obtained from pooled muscle sections treated with 125 mM sucrose, 5 
mM Tris-HCl pH 6.4, 6% of XT Tricine Running Buffer (Bio-Rad), 10% SDS, 10% Glycerol, 
5% β-mercaptoethanol. The samples were purified with the Pierce Compat-Able™ Protein 
Assay Preparation Reagent Set (Thermo Scientific) and the total protein concentration was 
determined with the Pierce BCA Protein Assay Kit (Thermo Scientific). Samples were 
denatured at 95°C for 5 minutes and 100 µg of protein were loaded onto Criterion XT Tris-
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acetate precast gel 3-8% (Bio-Rad). Membrane was probed with primary monoclonal 
antibodies directed against dystrophin (NCL-DYS1, 1:50, Leica Biosystems; or 
MANEX1011B, 1:50, kindly gifted by The Muscular Dystrophy Association Monoclonal 
Antibody Resource (Bartlett et al., 2000)) and α-actinin (1:1000, Sigma-Aldrich), followed by 
incubation with a sheep anti-mouse secondary antibody (horseradish peroxidase conjugated; 
1:15000) and Pierce ECL Western Blotting Substrate (Thermo Scientific). 
 
Immunohistochemistry 
TA sections of 12 µm were cut and examined for dystrophin expression using the NCL-DYS2 
monoclonal antibody (1:50; Leica Biosystems) and a goat anti-mouse secondary antibody 
Alexa 488 (1:1000; Life technologies). 
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The Paper Explained 
PROBLEM:  
AAV-U7-mediated exon-skipping strategy is a very promising therapy for Duchenne muscular 
dystrophy. However, in preclinical models dystrophin restoration decreases drastically after 
one year in treated muscles. This decline in benefit is strongly correlated with loss of the 
therapeutic AAV genomes, probably due to alterations of the dystrophic myofiber 
membranes. In the context of an AAV-U7 clinical trial for DMD, AAV genome fate in 
dystrophic muscles is of major importance since the viral capsid immunogenicity currently 
limits repeated treatment. 
 
RESULTS:  
To improve the membrane integrity of the dystrophic myofibers at the time of AAV-U7 
injection, mdx muscles were pre-treated with a single dose of peptide-phosphorodiamidate 
morpholino (PPMO) antisense oligonucleotides that induced temporary dystrophin 
expression at the sarcolemma. The PPMO pre-treatment allowed efficient maintenance of 
AAV genomes in mdx muscles and enhanced the long-term effect of AAV-U7 therapy with a 
ten-fold increase of the protein level after six months. It is also beneficial to AAV-mediated 
gene therapy with transfer of micro-dystrophin cDNAs into muscles. 
 
IMPACT:  
This combined approach will allow the use of lower and thus safer vector doses while 
maximizing long-term therapeutic efficacy for Duchenne patients. Considering that more than 
80% of DMD mutations are eligible for the personalized medicine involving the skipping of a 
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single or of multiple exons, this combined therapy approach could in theory benefit up to 80% 
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Fig. 1. Kinetics of dystrophin restoration at different AAV1-U7ex23 doses. Tibialis 
anterior (TA) muscles of mdx mice were injected with 1E+11 viral genomes (vg) (High dose), 
3E+10 vg (Intermediate dose) or 1E+10 vg (Low dose) of AAV1-U7ex23. Three mdx TAs 
were injected per group. The mice were sacrificed 3, 6 and 12 weeks later (3, 6 or 12w). (a) 
Dystrophin restoration was evaluated by western blotting with NCL-DYS1 monoclonal 
antibodies (upper panel) on whole protein extracts from the treated muscles (lower panel: α-
actinin). The result of one representative TA is shown per condition. (b) Dystrophin 
restoration was quantified by ImageJ software and expressed as the percentage of 
dystrophin expression in wild-type (wt) muscle. (c) Quantification of AAV vg by absolute 
Taqman qPCR in injected mdx TAs. AAV genome content is expressed as the AAV genome 
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number relative to the value obtained for the mdx muscles injected with low dose of AAV1-
U7ex23 at three weeks post-injection. The data presented in (b) and (c) represent the mean 
values of the three TAs per group ± SEM. One of two representative experiments is shown. 
n.s., non-significant, ***P≤0.0001, Student’s t-test.  
 
Fig. 2. Effect of dystrophin restoration by Pip6a-PMO pre-treatment on viral genome 
maintenance. (a) TAs from mdx and wt mice were injected with 1 nmole of Pip6a-PMO two 
weeks (-2w) before the injection of 1E+11 vg of the non-therapeutic AAV1-U7scr vector (day 
0, d0). Control mdx and wt TAs were injected with AAV1-U7scr vector alone. Four TAs were 
injected per group. The mice were sacrificed 3 weeks later (3w). (b) Dystrophin rescue 
monitored by immunostaining with the NCL-DYS2 monoclonal antibody on transverse 
sections of TA muscles. One representative immunostained section is shown per condition. 
(c) Dystrophin restoration evaluated by western blotting with NCL-DYS1 monoclonal 
antibodies (upper panel) on whole protein extracts from the PPMO-treated muscles (lower 
panel: α-actinin). Dystrophin restoration was quantified by ImageJ software and expressed 
as the percentage of dystrophin expression in wt muscle. (d) Quantification of AAV viral 
genomes by absolute Taqman qPCR. AAV genome content is expressed as the AAV 
genome number relative to the value obtained for the non PPMO-treated mdx muscles. The 
data represent the mean values of 4 muscles per group ± SEM. n. s.: non-significant, ***p < 
0.001, Student’s t-test. One of two representative experiments is shown.  
 
Fig. 3. Effect of Pip6a-PMO pre-treatment on long-term dystrophin rescue by low dose 
of AAV-U7ex23. (a) Mdx TAs were injected with 1 nmole of Pip6a-PMO two weeks (-2w) 
before the injection of 1E+10 vg of therapeutic AAV1-U7ex23 vector (day 0, d0). Control mdx 
TAs were injected with PPMO or AAV1-U7ex23 vector alone. Four TAs were injected per 
group. The mice were sacrificed 6 months later (6m). (b) Level of exon 23 skipping estimated 
by nested RT-PCR. The 901 bp PCR product corresponds to full-length dystrophin 
transcripts whereas the 688 bp product corresponds to transcripts lacking exon 23. (c) 
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Quantification of exon 23 skipping performed by relative TaqMan qPCR and expressed as a 
percentage of total dystrophin transcripts. (d) Quantification of AAV viral genomes by 
absolute Taqman qPCR. AAV genome content is expressed as the AAV genome number 
relative to the value obtained for the non PPMO-treated mdx muscles. The data presented in 
(c) and (d) represent the mean values of the four TAs per group ± SEM. *p < 0.05, ***p < 
0.001, Student’s t-test. (e) Dystrophin restoration evaluated by western blotting with NCL-
DYS1 monoclonal antibodies (upper panel) on whole protein extracts from the treated 
muscles (lower panel: α-actinin). Dystrophin restoration was quantified by ImageJ software 
and expressed as the percentage of dystrophin expression in wt muscle.  
 
Fig. 4. Effect of Pip6a-PMO pre-treatment on AAV1 mediated micro-dystrophin gene 
therapy. (a) Mdx TAs were injected with 1 nmole of Pip6a-PMO two weeks (-2w) before 
injection of 1E+10 vg of AAV1-MD1 micro-dystrophin expressing vector (day 0, d0). Control 
mdx TAs were injected with PPMO or AAV1-MD1 vector alone. Five TAs were injected per 
group. The mice were sacrificed 4 weeks later (4w). (b) Quantification of AAV viral genomes 
by absolute Taqman qPCR. AAV genome content is expressed as the AAV genome number 
relative to the value obtained for the non PPMO-treated mdx muscles. The data represent 
the mean values of the 5 muscles per group ± SEM. *p < 0.05, Student’s t-test. (c) 
Expression of PPMO-induced dystrophin (DYS, 427kDa) and micro-dystrophin (µDYS, 
132kDa) evaluated by western blotting with MANEX1011B monoclonal antibodies (upper 





Figure 1 wt  
mdx 
High Intermediate Low 





























































































































































































































































































55    77     74    63     52   62      3      1     22      % 
Supplementary data 1. Kinetics of dystrophin restoration by a single Pip6a-PMO intramuscular injection 
Two Tibialis anterior (TA) muscles of mdx mice were injected per group with 1nmole of Pip6a-PMO. Dystrophin 
expression was evaluated after 2 weeks (2w), 5 weeks (5w), 3 months (3m) and 6 months (6m), by western blotting 
with NCL-DYS1 monoclonal antibodies (upper panel) on whole protein extracts from the treated muscles (lower 
panel: α-actinin). Dystrophin restoration was quantified by ImageJ software and expressed as the percentage of wild-
type (wt) dystrophin expression. 
